Pharmaceutical company
Appears in 2 stories
Inventor of the antisense technology, Biogen's partner
For decades, nearly every Alzheimer's drug that reached patients aimed at one target: a sticky protein called amyloid. On July 14, 2026, Biogen showed the first clinical evidence that hitting a different protein, tau, can also slow the disease.
Updated Yesterday
Discovered salanersen; licensed it to Biogen
Some children with spinal muscular atrophy get a one-time gene therapy, then slowly weaken again. There has been no clear next step for them. On June 4, 2026, the FDA gave Biogen's salanersen a designation meant to speed up that next step.
Updated Jun 4
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
